- Between January and July 2004 in the US we managed 47 ongoing or complete clinical trials involving 202 initial serious adverse events/adverse events and follow-up on 331 cases
- In Europe for 2004, we managed 10 studies involving 2,274 serious adverse event cases and 1,949 follow-up cases
- During one pharmacovigilance project, we reviewed 1,756,796 records that included 17,902 serious adverse events, adverse events and suspected events requiring follow-up
- For another pharmacovigilance project, we reviewed 27,091 records and processed 10,117 cases
- In the first eight months of 2004, for one product alone we processed 3,412 adverse events
- We developed an electronic case triage and follow-up system, which saved our client $3.8 million in human effort time and $0.55 million in mailing costs
|
